Browse

Commercializing a rare disease therapy presents a high‑risk, high‑reward scenario for biotech firms. Small patient populations, stringent regulatory requirements, and the need to sustain value beyo…

John Carroll and Arsalan Arif launched Endpoints News a decade ago with no seed funding or investors, describing themselves as completely broke. They built the news service from scratch, relying on…